Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC

About this episode

Experts discuss the multidisciplinary care of patients with HER2-negative/ultralow/low metastatic breast cancer, focusing on antibody-drug conjugates.

Listen to Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, as they discuss multidisciplinary care of patients with HER2-negative/ultralow/low metastatic breast cancer, with a focus on ADCs.

People in this episode

Guests: Aditya Bardia, MD, MPH, FASCO, Ruta Rao, MD

Topics covered

• HER2-negative breast cancer
• metastatic breast cancer
• ADCs
• multidisciplinary care
• oncology

Keywords

• HER2-negative
• metastatic breast cancer
• ADCs
• oncology
• multidisciplinary care

Mentioned in this episode

Organizations: Decera Clinical Education

More episodes of Decera Clinical Education Oncology Podcast

• Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness · June 9, 2026 · 27 min
• HNSCC: Current and Emerging Therapeutic Strategies · May 29, 2026 · 26 min
• Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies · May 15, 2026 · 21 min
• Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma · May 7, 2026 · 31 min
• Thrombotic Events and ET/PV: What You Should Know · April 30, 2026 · 22 min
• Global Experts Discuss Current and Emerging Treatments for ET and PV · April 30, 2026 · 17 min